Rapid Micro BiosystemsRPID +0.59%60 Current Ratio is 2.57 as of Mar. 2026, which is 63% below its 10-year median of 6.93. GuruFocus rates RPID with a GF Score™ of 60/100 and a GF Value™ of $1.88 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Rapid Micro Biosystems ranks better than 52.46% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Rapid Micro Biosystems's current ratio for the quarter that ended in Mar. 2026 was 2.57.
Rapid Micro Biosystems has a current ratio of 2.57. It generally indicates good short-term financial strength.
The historical rank and industry rank for Rapid Micro Biosystems's Current Ratio or its related term are showing as below:
RPID'
s Current Ratio Range Over the Past 10 Years
Min: 2.24 Med: 6.93 Max: 13.78
Current: 2.57
During the past 7 years, Rapid Micro Biosystems's highest Current Ratio was 13.78. The lowest was 2.24. And the median was 6.93.
RPID's Current Ratio is ranked better than 52.46% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 2.485
vs RPID: 2.57
Rapid Micro Biosystems (NAS:RPID) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Rapid Micro Biosystems Current Ratio Related Terms
Rapid Micro Biosystems Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Rapid Micro Biosystems's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rapid Micro Biosystems Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Rapid Micro Biosystems's Current Ratio distribution charts can be found below:
* The bar in red indicates where Rapid Micro Biosystems's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rapid Micro Biosystems (RPID) has a Current Ratio of 2.57 as of Mar. 2026. This is 63% below median its historical median of 6.93. Over the past decade, Rapid Micro Biosystems' Current Ratio has ranged from 2.24 to 13.78. According to the industry distribution chart, Rapid Micro Biosystems ranks #406 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 47.5%.
Is Rapid Micro Biosystems' Current Ratio too high?
Rapid Micro Biosystems' current Current Ratio of 2.57 is 63% below median its 10-year median of 6.93. Over the past 10 years, this metric has ranged from a low of 2.24 to a high of 13.78. The Medical Devices & Instruments industry median Current Ratio is 2.49. Rapid Micro Biosystems' value of 2.57 is 3.4% above this industry median. Based on the distribution chart, Rapid Micro Biosystems ranks #406 out of 854 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Rapid Micro Biosystems has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rapid Micro Biosystems' Current Ratio compare to ZOMDF and STIM?
According to the Medical Devices & Instruments industry distribution chart, Rapid Micro Biosystems ranks #406 out of 854 companies for Current Ratio. This puts Rapid Micro Biosystems in the upper half of its industry. The industry median Current Ratio is 2.49. Rapid Micro Biosystems' value of 2.57 is 3.4% above this benchmark. Historically, Rapid Micro Biosystems' own Current Ratio has ranged from 2.24 to 13.78 over the past decade. While the company's 10-year median is 6.93 vs. the industry median of 2.49, Rapid Micro Biosystems has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.49, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rapid Micro Biosystems's current Current Ratio of 2.57 is 3.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rapid Micro Biosystems's current Current Ratio is 2.57, which is 63% below median its own 10-year median of 6.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Micro Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Rapid Micro Biosystems (RPID) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.88, compared to a current price of $1.70 — trading 9.6% below its estimated fair value. The current Current Ratio is 2.57, which is 63% below median its 10-year median of 6.93 and 3.4% above the Medical Devices & Instruments industry median of 2.49. Rapid Micro Biosystems' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Rapid Micro Biosystems (RPID), the current Current Ratio is 2.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rapid Micro Biosystems (RPID) Overvalued in 2026?
Based on GuruFocus' analysis, Rapid Micro Biosystems stock appears to be undervalued.
The current stock price of $1.70 is trading 9.6% below its estimated GF Value™ of $1.88.
GuruFocus considers Rapid Micro Biosystems to be Modestly Undervalued.
Key valuation signals for RPID:
Current Ratio: 2.57 (63% below median its 10-year median of 6.93)
GF Value™: $1.88 vs. price of $1.70 (9.6% below fair value)
Industry Position: 3.4% above the Medical Devices & Instruments median (#406 of 854)
No single metric tells the full story. See the RPID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.
60GF Score
Get the complete analysis for RPID
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPID has been successfully added to your 
